Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of WEVEE Vaccine in Healthy Adults
NCT03879603Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2019
- Primary completion
- Feb 2020
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of WEVEE VLP in Western equine encephalitis (WEE), eastern equine encephalitis (EEE) and Venezuelan equine encephalitis (VEE) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms, Number of Subjects Reporting Systemic Reactogenicity Signs and Symptoms and 3 more. Started Apr 2019; status: completed.
02
Drugs
WEVEE VLP
03
Conditions
Western equine encephalitis (WEE)eastern equine encephalitis (EEE)Venezuelan equine encephalitis (VEE)
Beyond the preview
Go deeper on NCT03879603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879603.